<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920762</url>
  </required_header>
  <id_info>
    <org_study_id>Assessment 7</org_study_id>
    <nct_id>NCT02920762</nct_id>
  </id_info>
  <brief_title>Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>ER/LA Opioid REMS Program Companies (RPC)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ER/LA Opioid REMS Program Companies (RPC)</source>
  <brief_summary>
    <textblock>
      A study will be performed to evaluate changes in prescribing behavior of prescribers of ER/LA
      opioids
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study will be performed to evaluate changes in prescribing behavior of prescribers.

        1. For products that are indicated for use in opioid-tolerant patients only (i.e., fentanyl
           transdermal patches, extended-release hydromorphone pills and extended-release morphine
           pills &gt;90mg), describe trends in the proportion of prescriptions for these products to
           opioid-non-tolerant patients in the year preceding the availability of REMS-compliant CE
           courses and compare the proportion of prescriptions to opioid non-tolerant patients pre-
           versus post-REMS CE course availability

        2. For products whose labels indicate that higher dosage strengths should only be used in
           opioid-tolerant patients, describe trends in the proportion of prescriptions prescribed
           to opioid non-tolerant patients with a high starting dosage strength; compare the
           proportion of prescriptions for such products that are prescribed to opioid non-tolerant
           patients with a high starting dosage strength pre- versus post-REMS CE course
           availability

        3. Describe trends in the proportion of prescriptions for ER/LA opioids prescribed to
           patients that have early refills of prescriptions and compare this proportion pre-
           versus post-REMS CE course availability.

        4. Compare the concomitant use of benzodiazepines with ER/LA opioids before and after REMS
           implementation.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monthly volume of opioid-tolerant patients prescribed products indicated for use only in opioid-tolerant patients</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly volume of opioid non-tolerant patients prescribed products indicated for use only in opioid-tolerant patients</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly volume of high-starting dose prescriptions in opioid-tolerant patients</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly volume of high starting dose prescriptions in non-opioid tolerant patients</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of opioid non-tolerant patients that have high-starting dose prescriptions</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of early refills by monthly patient cohort</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of normal refills (non-early refills) by monthly patient cohort</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving early refills</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Early refill rate by monthly patient cohort</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly volume of patients who are using a REMS product and a Benzodiazepine concomitantly</measure>
    <time_frame>Monthly over 54 months</time_frame>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">5575834</enrollment>
  <condition>Opioid Related Disorders</condition>
  <condition>Opiate Addiction</condition>
  <condition>Narcotic Abuse</condition>
  <condition>Drug Abuse</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone HCl</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine Sulfate</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine Sulfate Beads</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone HCl</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxymorphone HCl</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Tapentadol</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>on-interventional study - retrospective database review</intervention_name>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Hydromorphone HCl</arm_group_label>
    <arm_group_label>Morphine Sulfate</arm_group_label>
    <arm_group_label>Morphine Sulfate Beads</arm_group_label>
    <arm_group_label>Oxycodone HCl</arm_group_label>
    <arm_group_label>Oxymorphone HCl</arm_group_label>
    <arm_group_label>Tapentadol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects filling a prescription for a product of interest indicated for opioid-tolerant
        patients, filling prescriptions early and determining concomitant use of products as
        gathered from the IMS National prescription Audit™ and IMS Health, LifeLink™
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects filling a prescription for a product of interest during the specified time
             period will be included.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

